Free Trial

Entera Bio (ENTX) Stock Price, News & Analysis

Entera Bio logo
$1.81
-0.05 (-2.69%)
(As of 10/31/2024 ET)

About Entera Bio Stock (NASDAQ:ENTX)

Key Stats

Today's Range
$1.80
$1.86
50-Day Range
$1.65
$2.12
52-Week Range
$0.52
$3.35
Volume
10,630 shs
Average Volume
119,944 shs
Market Capitalization
$64.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
59th Percentile Overall Score

ENTX MarketRank™: 

Entera Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 505th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Entera Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Entera Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Entera Bio are expected to decrease in the coming year, from ($0.23) to ($0.53) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entera Bio is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entera Bio is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Entera Bio has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Entera Bio's valuation and earnings.
  • Percentage of Shares Shorted

    0.11% of the outstanding shares of Entera Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently decreased by 14.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Entera Bio does not currently pay a dividend.

  • Dividend Growth

    Entera Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.11% of the outstanding shares of Entera Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently decreased by 14.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Entera Bio has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Entera Bio this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Entera Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.90% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.11% of the stock of Entera Bio is held by institutions.

  • Read more about Entera Bio's insider trading history.
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Stock News Headlines

The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
See More Headlines

ENTX Stock Analysis - Frequently Asked Questions

Entera Bio's stock was trading at $0.60 on January 1st, 2024. Since then, ENTX stock has increased by 201.7% and is now trading at $1.81.
View the best growth stocks for 2024 here
.

Entera Bio Ltd. (NASDAQ:ENTX) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $0.06 million for the quarter.

Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and General Electric (GE).

Company Calendar

Last Earnings
8/09/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+452.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,890,000.00
Pretax Margin
-14,924.56%

Debt

Sales & Book Value

Annual Sales
$57,000.00
Book Value
$0.36 per share

Miscellaneous

Free Float
31,884,000
Market Cap
$64.77 million
Optionable
Optionable
Beta
1.57
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:ENTX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners